Heading

22. July 2011

Sarnen CH, Cambridge UK,  22th July 2011 OphthalmoPharma  announce that it has granted to Altacor exclusive licensing rights on its therapeutical compounds for the treatment of Dry Eye and Glaucoma.
Press release

-------------------

-------------------------------------------------------------------------------------------------------------------------------------------

21. Apr 2011

Sarnen CH, Cambridge UK,  21th April 2011 OphthalmoPharma and Altacor announce that they have concluded an exclusive, worldwide licensing agreement regarding EyeBar, a neutraceutical for the prevention of dry AMD. 

Altacor will be in charge of the sales of the product in UK and Irland as well as for the worldwide distribution.
Press release

-------------------

-------------------------------------------------------------------------------------------------------------------------------------------

14. Apr 2011

Sarnen CH, Cambridge UK,  14th April 2011 OphthalmoPharma and Altacor announce that they have today concluded an exclusive, worldwide licensing agreement regarding, OPPH’ proprietary, preloaded injector for delivery of intraocular lens in cataract and corrective lens replacement surgery (currently known as SOLO®).

This is the first in a series of transactions between Altacor and Ophthalmopharma in relation to its portfolio of ophthalmic products. Under the terms of the agreement, Altacor has assumed responsibility for all aspects of development, IP and commercialisation of the products.
Press release

 -------------------

 --------------------------------------------------------------------------------------------------------------------------------------------

31.Mar 2011

Please note OphthalmoPharma AG new phone numbers : 

Tel + 41 43 321 86 60 and Fax + 41 43 321 86 61

 -------------------

 --------------------------------------------------------------------------------------------------------------------------------------------

 24.Sep 2010

The WIPO assigns patent to OphthalmoPharma for "Device for holding and injecting an intraoccular lens" :SOLO

Geneva, Sept. 24 - Publication No. WO/2010/105678 was published on Sept. 23.According to the abstract posted by the World Intellectual Property Organization: "An injector (1) for folding and injecting into the eye of a patient a flexible intraocular lens, the injector comprising an assembly of an injection nozzle (202), a lens compartment that holds an unfolded flexible intraocular lens (400) and is in communication with the injection nozzle, an injector body (3) …link to related publication at the World Intellectual Property Organisation WIPO Applicants: OPHTHALMO PHARMA AG (CH).Inventors: Sebastien Putallaz (CH) and Laurent Pivard (FR).

 -------------------

 --------------------------------------------------------------------------------------------------------------------------------------------

3.Sept 2009

The Center for Drug Evaluation and Research of the Food and Drug Administration (CDER/FDA) has agreed in principle to accept our proposed product development plan, which entails the use of an abbreviated registration pathway, formally known as a 505(b)(2) New Drug Application (NDA), in order to obtain CDER/FDA approval of OphthalmoPharma’s Latanoprost CD Ophthalmic Solution product.

Sarnen CH, Sept. 17, 2009; Ophthalmopharma Ltd (OPPH) is pleased to report that the FDA has confirmed in a pre-IND meeting that an abbreviated registration pathway, the 505(b)(2) NDA, is an acceptable pathway for the registration of Latanoprost CD Ophthalmic Solution. This registration pathway includes a clinical development plan that begins with phase 2 and therefore considerably shortens development time for this product.

Latanoprost CD Ophthalmic Solution is in advanced pre-clinical stage of development. This new formulation is based on a proprietary cyclodextrin. The use of this naturally-derived, sugar-based substance imparts significant advantages to this formulation. Preclinical testing has suggested that Latanoprost CD will have better stability, lower side-effects, and better penetration to the eye than the original product (Xalatan®, Pfizer). Furthermore, the Latanoprost CD can be stored at room temperature and presented in a unit-dose, non-preservative-container.

-------------------

--------------------------------------------------------------------------------------------------------------------------------------------

3. July 2008

Motti Geron joins OphthalmoPharma as Global Projects Manager.

OphthalmoPharma is pleased to announce that Motti Geron has joined the Company as Projects Manager. His outstanding operational experience will be of particular value to the Company. Motti will be in charge of the projects management and coordination with top management and external partners.

Motti Geron has more than 20 years managerial experience in the Biotech and Pharmaceutical industries. He was responsible for successful process development and manufacturing of various Pharmaceutical and Diagnostic products, while serving as Process Development and Cell Culture Manager for Serono, Vice President of Operations for Procognia and Global Project Manager for Novartis. Prior to joining OphthalmoPharma, he has been an independent Project Management and BioProcessing consultant. Mr. Geron holds MSc degree in Applied Microbiology from Hebrew University of Jerusalem.

--------------------

 --------------------------------------------------------------------------------------------------------------------------------------------

17.Mar.2007

Dr. Christian Suter joins the OphthalmoPharma as Senior Project Manager

The Company has hired Dr. Christian Suter, an experienced pharmaceutical executive with extensive international experience, as senior project manager and strategic advisor. As a well known personality in the industry he will support OPPH to strengthen further its value creation efforts.

Christian Suter has 30 years experience in the life sciences industries. He was a pharma researcher at Roche, directed Vitamins Research, was head of manufacturing of Roche Pharmaceuticals in the US and Head of Global Vitamins R&D. Christian Suter studied chemistry at Basel University and UC Berkeley; he is an alumnus of the Harvard Business School Advanced Management Program.

--------------------

 ---------------------------------------------------------------------------------------------------------------------------------------------

14.Mar.2007

OphthalmoPharma has been granted the European Patent EP 1567094 related to its SOLO Intra-occular-lens injector.

OphthalmoPharma is pleased to announce that the European Patent Office has accorded the European Patent EP 1 567 094 for its “Method and Device for sterile packaging of a ready-to-use flexible hydrophilic intraocular lens”. This patent is associated with the SOLO™, our Intra-ocular-lens injector currently in late stage of development.